Jupiter Neurosciences Launches 狈耻驳别惫颈补鈩� Website and Opens Pre-Orders for Groundbreaking Longevity Supplements
Jupiter Neurosciences (NASDAQ: JUNS) has launched its 狈耻驳别惫颈补鈩� e-commerce platform, marking its entry into the $8 trillion global longevity market. The company is now accepting pre-orders for three nutraceutical supplements: 狈耻驳别惫颈补鈩� GLO, PWR, and MND, with shipping starting Fall 2025.
The products leverage Jupiter's patented 闯翱罢搁翱尝鈩� resveratrol delivery platform, which demonstrated a nine-fold increase in bioavailability in Phase I trials. This launch represents a dual-path business strategy, combining CNS therapeutic development with consumer health products. The company has also secured Hall of Fame golfer Annika S枚renstam and NBA legend Chris Webber as brand ambassadors.
Jupiter Neurosciences (NASDAQ: JUNS) ha lanciato la sua piattaforma e-commerce 狈耻驳别惫颈补鈩�, segnando il suo ingresso nel $8 trillion global longevity market. L'azienda accetta ora i preordini per tre integratori nutraceutici: 狈耻驳别惫颈补鈩� GLO, PWR e MND, con spedizioni previste per l'autunno 2025.
I prodotti sfruttano la piattaforma brevettata di somministrazione del resveratrolo 闯翱罢搁翱尝鈩� di Jupiter, che nei trial di Fase I ha mostrato un aumento della biodisponibilit脿 di nove volte. Questo lancio rappresenta una strategia aziendale a doppio binario, che combina lo sviluppo di terapie per il sistema nervoso centrale con prodotti per la salute dei consumatori. L'azienda ha inoltre ingaggiato la golfista Hall of Fame Annika S枚renstam e la leggenda NBA Chris Webber come ambasciatori del marchio.
Jupiter Neurosciences (NASDAQ: JUNS) ha lanzado su plataforma de comercio electr贸nico 狈耻驳别惫颈补鈩�, marcando su entrada en el $8 trillion global longevity market. La compa帽铆a ya acepta pedidos anticipados para tres suplementos nutrac茅uticos: 狈耻驳别惫颈补鈩� GLO, PWR y MND, con env铆os a partir del oto帽o de 2025.
Los productos aprovechan la plataforma patentada de administraci贸n de resveratrol 闯翱罢搁翱尝鈩� de Jupiter, que mostr贸 en los ensayos de Fase I un aumento de la biodisponibilidad de nueve veces. Este lanzamiento representa una estrategia comercial de doble v铆a, que combina el desarrollo de terapias para el SNC con productos de salud para consumidores. La compa帽铆a tambi茅n ha incorporado a la golfista del Sal贸n de la Fama Annika S枚renstam y a la leyenda de la NBA Chris Webber como embajadores de la marca.
Jupiter Neurosciences (NASDAQ: JUNS)臧� 狈耻驳别惫颈补鈩� 鞝勳瀽靸侁卑霝� 頂岆灚韽检潉 於滌嫓頃橂┌ $8 trillion global longevity market鞐� 歆勳稖頄堨姷雼堧嫟. 須岇偓電� 順勳灛 狈耻驳别惫颈补鈩� GLO, PWR, MND 霌� 靹� 臧�歆� 雺错姼霛检妶韹办滑 氤挫订鞝滌潣 鞓堨暯 欤茧鞚� 氚涥碃 鞛堨溂氅� 氚办啞鞚� 2025雲� 臧�鞚勲秬韯� 鞁滌瀾霅╇媹雼�.
鞚� 鞝滍拡霌れ潃 Jupiter鞚� 韸鬼棃氚涭潃 霠堨姢氩犽澕韸鸽· 鞝勲嫭 頂岆灚韽� 闯翱罢搁翱尝鈩�鞚� 頇滌毄頃橂┌, 1靸� 鞛勳儊鞐愳劀 靸濎泊鞚挫毄毳犾澊 9氚� 歃濌皜頃� 瓴冹溂搿� 雮橅儉雮姷雼堧嫟. 鞚措矆 於滌嫓電� 欷戩稊鞁犼步瓿�(CNS) 旃橂鞝� 臧滊皽瓿� 靻岆箘鞛� 瓯搓皶 鞝滍拡鞚� 氤戫枆頃橂姅 鞚挫 瓴诫 牍勳雼堨姢 鞝勲灥鞚� 鞚橂頃╇媹雼�. 霕愴暅 須岇偓電� 氇呾槇鞚� 鞝勲嫻鞐� 鞓るジ 瓿嵓 Annika S枚renstam瓿� NBA 鞝勳劋 Chris Webber毳� 敫岆灉霌� 頇嶋炒雽�靷 頇曤炒頄堨姷雼堧嫟.
Jupiter Neurosciences (NASDAQ: JUNS) a lanc茅 sa plateforme e鈥慶ommerce 狈耻驳别惫颈补鈩�, marquant son entr茅e sur le $8 trillion global longevity market. La soci茅t茅 accepte d茅sormais les pr茅commandes pour trois compl茅ments nutraceutiques : 狈耻驳别惫颈补鈩� GLO, PWR et MND, avec des exp茅ditions pr茅vues pour l'automne 2025.
Les produits s'appuient sur la plateforme brevet茅e d'administration de resv茅ratrol 闯翱罢搁翱尝鈩� de Jupiter, qui a montr茅 lors des essais de phase I une augmentation de la biodisponibilit茅 par neuf. Ce lancement illustre une strat茅gie commerciale 脿 double voie, alliant le d茅veloppement de th茅rapies SNC et des produits de sant茅 grand public. L'entreprise a 茅galement recrut茅 la golfeuse Hall of Fame Annika S枚renstam et la l茅gende de la NBA Chris Webber comme ambassadeurs de la marque.
Jupiter Neurosciences (NASDAQ: JUNS) hat seine E鈥慍ommerce鈥慞lattform 狈耻驳别惫颈补鈩� gestartet und damit den Einstieg in den $8 trillion global longevity market vollzogen. Das Unternehmen nimmt jetzt Vorbestellungen f眉r drei nutraceutical Supplements entgegen: 狈耻驳别惫颈补鈩� GLO, PWR und MND; der Versand beginnt im Herbst 2025.
Die Produkte basieren auf Jupiters patentierter Resveratrol鈥慙ieferplattform 闯翱罢搁翱尝鈩�, die in Phase鈥慖鈥慡tudien eine neunfach gesteigerte Bioverf眉gbarkeit zeigte. Dieser Launch steht f眉r eine Dual鈥慞ath鈥慓esch盲ftsstrategie, die die Entwicklung von ZNS鈥慣herapien mit Verbraucher鈥慓esundheitsprodukten kombiniert. Zudem hat das Unternehmen die Hall鈥憃f鈥慒ame鈥慓olferin Annika S枚renstam und NBA鈥慙egende Chris Webber als Markenbotschafter gewonnen.
- JOTROL platform showed 9x increased bioavailability in Phase I trials
- Entry into $8 trillion global longevity market creates new revenue stream
- Capital-efficient business model supporting ongoing R&D
- Partnership with high-profile brand ambassadors enhances market visibility
- Product revenue generation won't begin until Fall 2025
- Entering highly competitive nutraceutical market as a new player
Insights
Jupiter Neurosciences launching nutraceutical line leveraging clinical technology, creating new revenue stream while pursuing pharmaceutical development.
Jupiter Neurosciences has made a strategic move to capitalize on its pharmaceutical research by launching 狈耻驳别惫颈补鈩�, a consumer-focused supplement line targeting the
The most compelling aspect of this launch is how Jupiter is leveraging its clinically-validated 闯翱罢搁翱尝鈩� resveratrol delivery platform, which demonstrated a nine-fold increase in bioavailability in Phase I trials. This pharmaceutical technology transfer to consumer products creates a differentiated position in the crowded supplement space.
The initial product lineup strategically targets three distinct segments of the wellness market: 狈耻驳别惫颈补鈩� GLO for skin health, 狈耻驳别惫颈补鈩� PWR for mitochondrial function and energy, and 狈耻驳别惫颈补鈩� MND for cognitive support. Each combines 闯翱罢搁翱尝鈩� with another clinically-studied ingredient like NovaSOL庐 formulations.
From a financial perspective, this launch represents a capital-efficient strategy to generate near-term revenue that can potentially fund the company's pharmaceutical R&D pipeline. The subscription model offers recurring revenue potential, while the endorsement from high-profile ambassadors Annika S枚renstam and Chris Webber aims to accelerate market adoption.
While the press release is optimistic, investors should note that actual shipments won't begin until Fall 2025, and no specific revenue projections were provided. The success of this strategy depends on consumer adoption rates, conversion of pre-orders to sales, and the company's ability to scale its consumer business alongside its pharmaceutical research operations.
Targeting the Multi-Trillion Dollar Longevity Market
Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (鈥淛upiter鈥� or the 鈥淐ompany鈥�), a clinical-stage pharmaceutical company pioneering therapies for central nervous system (CNS) disorders and advancing science-based consumer health solutions, today announced a pivotal expansion of its dual-path business model with the launch of its dedicated Nugevia鈩� e-commerce website, , and the opening of pre-orders for its first three nutraceutical supplements: Nugevia鈩� GLO, Nugevia鈩� PWR, and Nugevia鈩� MND. The products are available for purchase via subscription or as a one-time order, with shipping scheduled to begin this Fall.
Leveraging Clinical Science to Create a Commercial Advantage through Consumer Health
The Nugevia product line is founded on Jupiter鈥檚 patented JOTROL鈩� resveratrol delivery platform which demonstrated a nine-fold increase in bioavailability in Phase I clinical trials. By capitalizing on this clinical data, Jupiter is introducing pharmaceutical-grade science to the longevity marketplace. The Company is strategically executing a dual-path business model that simultaneously advances its CNS therapeutic programs while capturing value in the
- Nugevia鈩� GLO promotes skin vitality and cellular defense by combining JOTROL鈩� with NovaSOL庐 Astaxanthin, targeting the expanding "beauty-from-within" market.
- Nugevia鈩� PWR enhances mitochondrial health, endurance, and recovery by combining JOTROL鈩� with highly bioavailable NovaSOL庐 CoQ10.
- Nugevia鈩� MND supports memory, focus, and cognitive resilience through a unique pairing of JOTROL鈩� and NovaSOL庐 Curcumin, addressing neuroinflammation and oxidative stress.
鈥淭he launch of Nugevia鈩� represents a pivotal inflection point for Jupiter Neurosciences,鈥� said Christer Ros茅n, Chairman and CEO of Jupiter Neurosciences. 鈥淲e are leveraging the culmination of decades of CNS research and our clinically validated JOTROL鈩� technology to establish a new, capital-efficient growth engine by giving consumers access to clinically validated wellness products. Launching the Nugevia website and enabling pre-orders is a significant milestone we have looked forward to for several years, and investors should view this as a powerful step forward in our strategy to build a diversified and sustainable business that complements and supports the research and development of our pharmaceutical pipeline.鈥�
A Capital-Efficient Growth Strategy
The Nugevia launch serves as the foundation of a new commercial channel that directly complements the Company鈥檚 clinical development programs. By building a premium consumer longevity product line rooted in clinical science, the Company is creating a near-term revenue stream that supports ongoing R&D and enhances financial flexibility.
Introducing Nugevia鈩� Brand Ambassadors
Hall of Fame golfer Annika S枚renstam and NBA legend Chris Webber have been named as our first two Nugevia鈩� brand ambassadors. Both bring global visibility and credibility, reinforcing our brand alignment with high performance, healthy aging, and scientific innovation.
Availability
Pre-orders for Nugevia鈩� GLO, PWR, and MND are now available at . Consumers can choose flexible subscription options or one-time purchases, with product delivery starting in Fall 2025.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia鈩� product line. Both efforts are powered by JOTROL鈩�, Jupiter鈥檚 proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company鈥檚 prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson鈥檚 disease, including indications such as Alzheimer鈥檚 Disease, Mucopolysaccharidoses Type I, Friedreich鈥檚 Ataxia, and MELAS. More information may be found on the Company鈥檚 website聽.
About JOTROL
Resveratrol is one of the world鈥檚 most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL鈩� achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer鈥檚 Disease trial, and Yui et al., Friedreich鈥檚 Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL鈩� trials, were published in the Journal of Alzheimer鈥檚 Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL鈩� toward a Phase IIa trial in Parkinson鈥檚 Disease.
In addition to its therapeutic applications, JOTROL鈩� serves as the foundation for Jupiter鈥檚 Nugevia鈩� consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia鈩� introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company鈥檚 current expectations, including the Company鈥檚 ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 鈥渁pproximates,鈥� 鈥渂elieves,鈥� 鈥渉opes,鈥� 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渆stimates,鈥� 鈥減rojects,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渕ay鈥� or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company鈥檚 final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company鈥檚 securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
FAQ
What products did Jupiter Neurosciences (JUNS) launch in August 2025?
How effective is Jupiter Neurosciences' JOTROL technology?
When will Jupiter Neurosciences (JUNS) begin shipping Nugevia products?
Who are the brand ambassadors for Jupiter Neurosciences' Nugevia products?
What is Jupiter Neurosciences' (JUNS) business strategy?
